including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View more
The annual global premier event in nuclear medicine and molecular imaging, the 2026 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), has officially kicked off.
View moreRadiopharma Is Building at Record Speed. The Talent Pool Isn’t
Why Terbium-161 Could Be Nuclear Medicine’s Next Blockbuster Isotope
Can Alpha Therapy Stay Local? Oncoinvent’s Radspherin Data Point to Low Normal-Organ Exposure
ITM’s FDA Setback Points to a Growing Radiopharma Problem: Manufacturing Readiness
Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology
PET/CT predicts response to neoadjuvant therapy in breast cancer
